HealthcareMid capRs 16,581 crRs 11.5 cr traded a day
Close on 2026-08-21
1,350.90
−1.39%
52-week range91% of the way up
860.051,398.70
Market cap
16,581 cr
P/E (TTM)
27.5×
industry 44×
EPS (TTM)
49.13
Revenue YoY
+6.4%
Q1 FY27
Profit YoY
+31.7%
Net margin
25.0%
+4.8pt vs a year ago
Growth trend
+0.3pt
vs last quarter’s YoY
1 month
+22.5%
Below 52w high
3.5%
RSI (14)
71
overbought
Daily swing
3.9%
average true range
Volume
0.4×
vs 20-day average
Traded
Rs 12 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−2.58%
1 month
+22.50%
3 months
+23.86%
6 months
+46.83%
1 year
+44.52%
The read
written from the numbers on this page
The evidence leans constructive8 supporting, 0 against, 0 worth knowing
Supporting
trading 33% above its 200-day average
sitting at 91% of its 52-week range, with little overhead supply from trapped buyers
up 45% over twelve months
matches the market's strongest stocks, which has beaten the market by +0.37 points over 20 sessions across 48,607 past signals
3 independent kinds of evidence agree today, which is uncommon
revenue grew 6% year on year in the quarter ending 2026-06-30
net margin has widened from 22.1% to 25.0% across four quarters
priced at 27× earnings against an industry median of 44× — 38% below its peers
Against
nothing the data supports either way
Worth knowing
nothing the data supports either way
What would change this read: a close below 1,019, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net margin moved from 20.2% to 25.0%.
20.2%25.0%
Profit rose year on year in all 4 of the last 4 quarters.
4
Net profit +31.7% year on year, Rs 122 cr to Rs 160 cr.
+31.7%Rs 122 crRs 160 cr
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
7 of 47 matched on 2026-08-21
ALIVUS matches 7 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
ALIVUS trades at 27× trailing earnings, above its median of 25× over this window — 9% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
M&A filings were typically +0.23pt vs the market over the next 5 sessions (n=981) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 6% against the same quarter a year earlier
profit rose 32% year on year
net margin widened from 23.6% to 25.0%
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · standalone
640
212
160
13.04
25.0%
Q4 FY26
2026-03-31 · standalone
689
216
163
13.23
23.6%
Q3 FY26
2025-12-31 · standalone
673
198
150
12.25
22.3%
Q2 FY26
2025-09-30 · standalone
588
174
130
10.60
22.1%
Q1 FY26
2025-06-30 · standalone
602
163
122
9.91
20.2%
Q4 FY25
2025-03-31 · standalone
650
191
142
11.57
21.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+13.3%
Versus 200-day average+32.6%
Below 52-week high-3.4%
Above 52-week low+57.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)71.3
Higher closes in last 53 of 5
Six-month return+46.83%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.89%
Volume versus 20-day0.4x
Median daily turnoverRs 11.5 cr
Peers
Healthcare · 67 classified companies
ALIVUS trades at 27.5× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 38%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.